The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of  a patient a harbinger of hefty prices the new drugs are expected to command in the US and Europe in coming months The drug Opdivo from Ono Pharmaceutical Co and BristolMyers Squibb Co is a socalled PD inhibitor a new type of drug that harnesses the bodys immune system to fight tumors including melanoma Several other pharmaceutical companies are also developing PD targeting drugs 